Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2010

View Archived Issues

Apilimod mesilate has limited efficacy in phase II trial in rheumatoid arthritis

Dose increase authorized in Neovacs' ongoing IFN-alpha-kinoid phase I/II trial in SLE

BioSante Pharma sells Cold Genesys rights to its oncolytic virus technology

Nautilus and Tribute enter Canadian license agreement for Cambia to treat migraine

Lilly describes activity of LY-2606368, now in phase I testing

New HIF-1-alpha inhibitor P-2630 demonstrates oncolytic activity in vivo

Promising new antimalarial candidates investigated in preclinical testing

Spanish scientists present new inhibitors of PI3K/mTOR

Ampla Pharmaceuticals identifies novel cyclic amides

Theravance discloses novel inhibitors of 5HTT and NET

Cardero Therapeutics claims new inhibitors of mitochondrial permeability transition

St. Jude Medical acquires AGA Medical

FDA approves ready-to-use Nexterone premixed injection

Immunovaccine's phase I/II DPX-Survivac testing will target ovarian cancer

Fast Forward and Provid Pharma expand partnership to develop PV-267 in MS

Neuralstem submits IND to FDA for phase I trials of NSI-189 for depression

Halcygen Pharmaceuticals becomes Mayne Pharma Group

University of Michigan describes new 1,4-benzodiazepinone derivatives

Inspiration Biopharmaceuticals starts treatment in pivotal OBI-1 study

YM BioSciences expands phase I/II CYT-387 trial

BTG acquires Biocompatibles

Primary endpoint met in phase IIb Remimazolam trial in patients undergoing colonoscopy

Bayer and Regeneron report topline phase III data on VEGF Trap-Eye in wet AMD

Sylentis begins phase I/II SYL-040012 trial in patients with ocular hypertension

STATegics receives award from U.S. DoD to advance erythropoietin mimetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...